• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

15种抗菌药物对科威特艰难梭菌临床分离株的体外活性

In vitro activity of 15 antimicrobial agents against clinical isolates of Clostridium difficile in Kuwait.

作者信息

Jamal Wafaa Y, Mokaddas Eiman M, Verghese Tina L, Rotimi V O

机构信息

Department of Microbiology, Faculty of Medicine, Kuwait University and Mubarak Al-Kabeer Teaching Hospital, P.O. Box 24923, 13110, Safat, Kuwait.

出版信息

Int J Antimicrob Agents. 2002 Oct;20(4):270-4. doi: 10.1016/s0924-8579(02)00180-2.

DOI:10.1016/s0924-8579(02)00180-2
PMID:12385683
Abstract

A total of 73 clinical isolates of Clostridium difficile isolated from stool/rectal swabs of patients admitted to the intensive care units at Mubarak Hospital, Ibn Sina Hospital Burn unit and Haematology wards at the Kuwait Cancer Control Centre, were investigated for their susceptibility to 15 antibiotics using the Etest. Amoxycillin-clavulanic acid, ampicillin, meropenem, metronidazole, penicillin, piperacillin, piperacillin/tazobactam, teicoplanin and vancomycin had excellent activities with MIC(90)s of 0.38, 0.5, 1, 0.19, 1.5, 2, 3, 0.25 and 0.75 mg/l, respectively. Of the 73 C. difficile isolates, 86% were resistant to imipenem (MIC(90) >32 mg/l) and almost 97% were resistant to trovafloxacin (MIC(90)>256 mg/l). Forty eight percent of the isolates were resistant to clindamycin. A total of 18 isolates were highly clindamycin-resistant with an MIC of >256 mg/l; 10 of these were toxin producers. Multiple antibiotic resistance (two or more antibiotics) was noted in 63 isolates. These were more common among the toxigenic strains than the non-toxigenic strains by a ratio of 2.5:1.

摘要

从穆巴拉克医院重症监护病房、伊本·西那医院烧伤科以及科威特癌症控制中心血液科病房的患者粪便/直肠拭子中分离出73株艰难梭菌临床分离株,使用Etest法检测它们对15种抗生素的敏感性。阿莫西林-克拉维酸、氨苄西林、美罗培南、甲硝唑、青霉素、哌拉西林、哌拉西林/他唑巴坦、替考拉宁和万古霉素具有优异的活性,其MIC(90)分别为0.38、0.5、1、0.19、1.5、2、3、0.25和0.75mg/l。在73株艰难梭菌分离株中,86%对亚胺培南耐药(MIC(90)>32mg/l),近97%对曲伐沙星耐药(MIC(90)>256mg/l)。48%的分离株对克林霉素耐药。共有18株分离株对克林霉素高度耐药,MIC>256mg/l;其中10株产生毒素。63株分离株存在多重抗生素耐药(对两种或更多种抗生素耐药)。这些在产毒菌株中比非产毒菌株更常见,比例为2.5:1。

相似文献

1
In vitro activity of 15 antimicrobial agents against clinical isolates of Clostridium difficile in Kuwait.15种抗菌药物对科威特艰难梭菌临床分离株的体外活性
Int J Antimicrob Agents. 2002 Oct;20(4):270-4. doi: 10.1016/s0924-8579(02)00180-2.
2
Surveillance of Antibiotic Resistance among Hospital- and Community-Acquired Toxigenic Clostridium difficile Isolates over 5-Year Period in Kuwait.科威特5年期间医院和社区获得性产毒艰难梭菌分离株的抗生素耐药性监测
PLoS One. 2016 Aug 18;11(8):e0161411. doi: 10.1371/journal.pone.0161411. eCollection 2016.
3
Surveillance and trends of antimicrobial resistance among clinical isolates of anaerobes in Kuwait hospitals from 2002 to 2007.2002 年至 2007 年科威特医院临床分离厌氧菌的抗菌药物耐药性监测及趋势。
Anaerobe. 2010 Feb;16(1):1-5. doi: 10.1016/j.anaerobe.2009.04.004. Epub 2009 May 4.
4
Changes in sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric in-patients over an 18-month period.
J Med Microbiol. 2003 Mar;52(Pt 3):259-263. doi: 10.1099/jmm.0.05037-0.
5
Antimicrobial susceptibility patterns of Clostridium difficile strains belonging to different polymerase chain reaction ribotypes isolated in Poland in 2012.2012年在波兰分离出的属于不同聚合酶链反应核糖体分型的艰难梭菌菌株的抗菌药敏模式。
Anaerobe. 2015 Feb;31:37-41. doi: 10.1016/j.anaerobe.2014.09.004. Epub 2014 Sep 19.
6
High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China. fidaxomicin 对中国一所教学医院艰难梭菌分离株的体外高活性。
J Microbiol Immunol Infect. 2018 Jun;51(3):411-416. doi: 10.1016/j.jmii.2017.06.007. Epub 2017 Jun 29.
7
Antibacterial activity of teicoplanin against Clostridium difficile.替考拉宁对艰难梭菌的抗菌活性。
Southeast Asian J Trop Med Public Health. 1996 Sep;27(3):606-9.
8
In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993-2007 in Sweden.1993-2007 年在瑞典收集的临床艰难梭菌分离株对 17 种抗菌药物的体外敏感性。
Clin Microbiol Infect. 2010 Aug;16(8):1104-10. doi: 10.1111/j.1469-0691.2009.03048.x. Epub 2009 Sep 3.
9
Antimicrobial susceptibility of Clostridium difficile isolated from food and environmental sources in Western Australia.西澳大利亚州食源和环境源艰难梭菌的抗菌药敏性。
Int J Antimicrob Agents. 2018 Sep;52(3):411-415. doi: 10.1016/j.ijantimicag.2018.05.013. Epub 2018 May 23.
10
[In Vitro Activities of Antimicrobials Against Toxigenic Clostridioides difficile Isolates Obtained in a University Training and Research Hospital in Turkey].[土耳其一家大学培训与研究医院分离出的产毒艰难梭菌分离株对抗菌药物的体外活性]
Mikrobiyol Bul. 2020 Jul;54(3):368-377. doi: 10.5578/mb.69427.

引用本文的文献

1
In Vitro Activity of Dalbavancin and Fourteen Other Antimicrobial Agents Against Toxigenic Clostridioides Difficile Clinical Isolates in a Greek Tertiary-Care Hospital.达巴万星及其他十四种抗菌药物对希腊一家三级护理医院产毒艰难梭菌临床分离株的体外活性
Med Princ Pract. 2024 Mar 20;33(4):392-8. doi: 10.1159/000538414.
2
Novel ribotype/sequence type associations and diverse CRISPR-Cas systems in environmental Clostridioides difficile strains from northern Iraq.来自伊拉克北部环境艰难梭菌的新型核糖体分型/序列型关联和多样化的 CRISPR-Cas 系统。
FEMS Microbiol Lett. 2023 Jan 17;370. doi: 10.1093/femsle/fnad091.
3
Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis.
艰难梭菌(梭状芽孢杆菌属)源于人类的抗微生物药物耐药性:系统评价和荟萃分析。
Antimicrob Resist Infect Control. 2020 Sep 25;9(1):158. doi: 10.1186/s13756-020-00815-5.
4
Prevalence and antimicrobial susceptibility pattern of toxigenic Clostridium difficilestrains isolated in Iran.伊朗分离的产毒艰难梭菌的流行情况和药敏模式。
Turk J Med Sci. 2019 Feb 11;49(1):384-391. doi: 10.3906/sag-1808-11.
5
Surveillance of Antibiotic Resistance among Hospital- and Community-Acquired Toxigenic Clostridium difficile Isolates over 5-Year Period in Kuwait.科威特5年期间医院和社区获得性产毒艰难梭菌分离株的抗生素耐药性监测
PLoS One. 2016 Aug 18;11(8):e0161411. doi: 10.1371/journal.pone.0161411. eCollection 2016.
6
Fecal microbiota transplantation for severe clostridium difficile infection after left ventricular assist device implantation: a case control study and concise review on the local and regional therapies.左心室辅助装置植入术后严重艰难梭菌感染的粪便微生物群移植:一项病例对照研究及对局部和区域治疗的简要综述
BMC Infect Dis. 2016 May 27;16:234. doi: 10.1186/s12879-016-1571-6.
7
Association of tcdA+/tcdB+ Clostridium difficile Genotype with Emergence of Multidrug-Resistant Strains Conferring Metronidazole Resistant Phenotype.tcdA+/tcdB+艰难梭菌基因型与赋予甲硝唑耐药表型的多重耐药菌株出现的关联。
Iran Biomed J. 2015;19(3):143-8. doi: 10.7508/ibj.2015.03.003. Epub 2015 Jun 6.
8
Antimicrobial susceptibility of clostridium difficile clinical isolates in iran.伊朗艰难梭菌临床分离株的抗菌药敏性
Iran Red Crescent Med J. 2013 Aug;15(8):704-11. doi: 10.5812/ircmj.5189. Epub 2013 Aug 5.
9
Treatment of refractory and recurrent Clostridium difficile infection.难辨梭状芽孢杆菌感染的难治性和复发性治疗。
Nat Rev Gastroenterol Hepatol. 2011 Jun;8(6):330-9. doi: 10.1038/nrgastro.2011.59. Epub 2011 Apr 19.
10
Anaerobic infections: update on treatment considerations.厌氧感染:治疗注意事项的最新进展。
Drugs. 2010 May 7;70(7):841-58. doi: 10.2165/11534490-000000000-00000.